Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment

Background Systemic inflammation is a key factor in tumor growth. C-reactive protein and albumin are parameters of systemic inflammation from the Glasgow Prognostic Score (GPS). The purpose was to evaluate the prognostic role of GPS in a homogeneous population of gastric cancer patients undergoing s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Surgery 2016-06, Vol.159 (6), p.1548-1556
Hauptverfasser: Melling, Nathaniel, MD, Grüning, Amica, MD, Tachezy, Michael, MD, Nentwich, Michael, MD, Reeh, Matthias, MD, Uzunoglu, Faik G., MD, Vashist, Yogesh K., MD, Izbicki, Prof, Jakob R., MD, Bogoevski, Dean, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1556
container_issue 6
container_start_page 1548
container_title Surgery
container_volume 159
creator Melling, Nathaniel, MD
Grüning, Amica, MD
Tachezy, Michael, MD
Nentwich, Michael, MD
Reeh, Matthias, MD
Uzunoglu, Faik G., MD
Vashist, Yogesh K., MD
Izbicki, Prof, Jakob R., MD
Bogoevski, Dean, MD
description Background Systemic inflammation is a key factor in tumor growth. C-reactive protein and albumin are parameters of systemic inflammation from the Glasgow Prognostic Score (GPS). The purpose was to evaluate the prognostic role of GPS in a homogeneous population of gastric cancer patients undergoing surgical treatment only. Methods Patients underwent operations between 2009 and 2014. Those who had received perioperative treatment or had other malignancies or inflammatory diseases were excluded. Eighty-eight patients met all inclusion criteria (age >18 years, documented preoperative serum levels of albumin and C-reactive protein, histologically proven gastric cancer, curative operation, including lymphadenectomy). C-reactive protein and albumin levels were retrieved from our prospective database. GPS was correlated with clinicopathologic characteristics and outcome. Results Increasing GPS was linked to aggressive tumor biology in terms of tumor size (GPS 0: 51.2% T1 and T2, 48.8% T3 and T4; GPS 1: 23.8% T1 and T2, 76.2% T3 and T4; GPS 2: 23.1% T1 and T2, 76.9% T3 and T4; P  = .026), synchronous distant metastases (GPS 0: 47.1% M0, 0.0% M1; GPS 1: 25.9% M0, 0.0% M1; GPS 2: 27.1% M0, 100.0% M1; P  = .030), venous vessel invasion (GPS 0: 91.2% V0, 8.8% V1; GPS 1: 66.7% V0, 33.3% V1; GPS 2: 55.0% V0, 45.0% V1; P  = .008), resection margin status (GPS 0: 97.4% R0, 2.6% R1; GPS 1: 90.0% R0, 10.0% R1; GPS 2: 77.3% R0, 22.7% R1; P  = .044), reduced overall survival (GPS 0: median 25.2 months [range 0.4–106.0]; GPS 1: 15.3 [0.2–59.5]; GPS 2: 5.8 [0.1–55.3]; P  = .016) with median overall survival in the whole cohort being 16.2 months (range 0.1–106.0) and perioperative mortality (GPS 0: 0.0% of perioperative deaths, GPS 1: 20.0%, GPS 2: 80.0%; P  = .036). Furthermore, GPS was identified as an independent prognosticator of overall survival ( P  = .033). A gradual decrease in survival between GPS subgroups was evident. Conclusion GPS represents an independent prognostic factor for long-term outcome in resected gastric cancer patients without perioperative treatment and is strongly associated with perioperative mortality.
doi_str_mv 10.1016/j.surg.2016.01.018
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1787096955</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0039606016000684</els_id><sourcerecordid>1787096955</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-6b59e588ac0599e755fdd4562cdedfebe98562f29bd0183be11af1e548480fc83</originalsourceid><addsrcrecordid>eNp9Ut2K1DAYDaK44-gLeCG59KZj0jZpAiLIoquwoLB6HdLk65gxbcYk7TrP4EubMqvCXgghP-Sck3znfAg9p2RHCeWvDrs0x_2uLvsdoWWIB2hDWVNXXcPpQ7QhpJEVJ5xcoCcpHQghsqXiMbqouZCy7egG_bryOu3DLf4cw34KKTuDb0yIgEd9wj1gjY__btxk4SceQsRhgai9x3qy-AjRhTLp7BbA5U-LW7QvYLzXKcfCM3oyEPGty9_CnO8RcgSdR5jyU_Ro0D7Bs7t1i76-f_fl8kN1_enq4-Xb68q0lOaK90wCE0IbwqSEjrHB2pbx2liwA_QgRTkMtextsaTpgVI9UGCtaAUZjGi26OVZt1T2Y4aU1eiSAe_1BGFOinaiI5JLxgq0PkNNDClFGNQxulHHk6JErSGog1pDUGsIilC1vrhFL-70534E-5fyx_UCeH0GQKlycRBVMg6KRdZFMFnZ4P6v_-Ye3Xg3OaP9dzhBOoQ5TsU_RVWqFVE3axusXUB56QAu2uY34puxeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1787096955</pqid></control><display><type>article</type><title>Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Melling, Nathaniel, MD ; Grüning, Amica, MD ; Tachezy, Michael, MD ; Nentwich, Michael, MD ; Reeh, Matthias, MD ; Uzunoglu, Faik G., MD ; Vashist, Yogesh K., MD ; Izbicki, Prof, Jakob R., MD ; Bogoevski, Dean, MD</creator><creatorcontrib>Melling, Nathaniel, MD ; Grüning, Amica, MD ; Tachezy, Michael, MD ; Nentwich, Michael, MD ; Reeh, Matthias, MD ; Uzunoglu, Faik G., MD ; Vashist, Yogesh K., MD ; Izbicki, Prof, Jakob R., MD ; Bogoevski, Dean, MD</creatorcontrib><description>Background Systemic inflammation is a key factor in tumor growth. C-reactive protein and albumin are parameters of systemic inflammation from the Glasgow Prognostic Score (GPS). The purpose was to evaluate the prognostic role of GPS in a homogeneous population of gastric cancer patients undergoing surgical treatment only. Methods Patients underwent operations between 2009 and 2014. Those who had received perioperative treatment or had other malignancies or inflammatory diseases were excluded. Eighty-eight patients met all inclusion criteria (age &gt;18 years, documented preoperative serum levels of albumin and C-reactive protein, histologically proven gastric cancer, curative operation, including lymphadenectomy). C-reactive protein and albumin levels were retrieved from our prospective database. GPS was correlated with clinicopathologic characteristics and outcome. Results Increasing GPS was linked to aggressive tumor biology in terms of tumor size (GPS 0: 51.2% T1 and T2, 48.8% T3 and T4; GPS 1: 23.8% T1 and T2, 76.2% T3 and T4; GPS 2: 23.1% T1 and T2, 76.9% T3 and T4; P  = .026), synchronous distant metastases (GPS 0: 47.1% M0, 0.0% M1; GPS 1: 25.9% M0, 0.0% M1; GPS 2: 27.1% M0, 100.0% M1; P  = .030), venous vessel invasion (GPS 0: 91.2% V0, 8.8% V1; GPS 1: 66.7% V0, 33.3% V1; GPS 2: 55.0% V0, 45.0% V1; P  = .008), resection margin status (GPS 0: 97.4% R0, 2.6% R1; GPS 1: 90.0% R0, 10.0% R1; GPS 2: 77.3% R0, 22.7% R1; P  = .044), reduced overall survival (GPS 0: median 25.2 months [range 0.4–106.0]; GPS 1: 15.3 [0.2–59.5]; GPS 2: 5.8 [0.1–55.3]; P  = .016) with median overall survival in the whole cohort being 16.2 months (range 0.1–106.0) and perioperative mortality (GPS 0: 0.0% of perioperative deaths, GPS 1: 20.0%, GPS 2: 80.0%; P  = .036). Furthermore, GPS was identified as an independent prognosticator of overall survival ( P  = .033). A gradual decrease in survival between GPS subgroups was evident. Conclusion GPS represents an independent prognostic factor for long-term outcome in resected gastric cancer patients without perioperative treatment and is strongly associated with perioperative mortality.</description><identifier>ISSN: 0039-6060</identifier><identifier>EISSN: 1532-7361</identifier><identifier>DOI: 10.1016/j.surg.2016.01.018</identifier><identifier>PMID: 26899471</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; C-Reactive Protein - metabolism ; Carcinoma - mortality ; Carcinoma - pathology ; Carcinoma - surgery ; Female ; Gastrectomy ; Humans ; Lymph Node Excision ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Serum Albumin ; Severity of Illness Index ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Stomach Neoplasms - surgery ; Surgery ; Survival Rate</subject><ispartof>Surgery, 2016-06, Vol.159 (6), p.1548-1556</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-6b59e588ac0599e755fdd4562cdedfebe98562f29bd0183be11af1e548480fc83</citedby><cites>FETCH-LOGICAL-c411t-6b59e588ac0599e755fdd4562cdedfebe98562f29bd0183be11af1e548480fc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0039606016000684$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26899471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Melling, Nathaniel, MD</creatorcontrib><creatorcontrib>Grüning, Amica, MD</creatorcontrib><creatorcontrib>Tachezy, Michael, MD</creatorcontrib><creatorcontrib>Nentwich, Michael, MD</creatorcontrib><creatorcontrib>Reeh, Matthias, MD</creatorcontrib><creatorcontrib>Uzunoglu, Faik G., MD</creatorcontrib><creatorcontrib>Vashist, Yogesh K., MD</creatorcontrib><creatorcontrib>Izbicki, Prof, Jakob R., MD</creatorcontrib><creatorcontrib>Bogoevski, Dean, MD</creatorcontrib><title>Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment</title><title>Surgery</title><addtitle>Surgery</addtitle><description>Background Systemic inflammation is a key factor in tumor growth. C-reactive protein and albumin are parameters of systemic inflammation from the Glasgow Prognostic Score (GPS). The purpose was to evaluate the prognostic role of GPS in a homogeneous population of gastric cancer patients undergoing surgical treatment only. Methods Patients underwent operations between 2009 and 2014. Those who had received perioperative treatment or had other malignancies or inflammatory diseases were excluded. Eighty-eight patients met all inclusion criteria (age &gt;18 years, documented preoperative serum levels of albumin and C-reactive protein, histologically proven gastric cancer, curative operation, including lymphadenectomy). C-reactive protein and albumin levels were retrieved from our prospective database. GPS was correlated with clinicopathologic characteristics and outcome. Results Increasing GPS was linked to aggressive tumor biology in terms of tumor size (GPS 0: 51.2% T1 and T2, 48.8% T3 and T4; GPS 1: 23.8% T1 and T2, 76.2% T3 and T4; GPS 2: 23.1% T1 and T2, 76.9% T3 and T4; P  = .026), synchronous distant metastases (GPS 0: 47.1% M0, 0.0% M1; GPS 1: 25.9% M0, 0.0% M1; GPS 2: 27.1% M0, 100.0% M1; P  = .030), venous vessel invasion (GPS 0: 91.2% V0, 8.8% V1; GPS 1: 66.7% V0, 33.3% V1; GPS 2: 55.0% V0, 45.0% V1; P  = .008), resection margin status (GPS 0: 97.4% R0, 2.6% R1; GPS 1: 90.0% R0, 10.0% R1; GPS 2: 77.3% R0, 22.7% R1; P  = .044), reduced overall survival (GPS 0: median 25.2 months [range 0.4–106.0]; GPS 1: 15.3 [0.2–59.5]; GPS 2: 5.8 [0.1–55.3]; P  = .016) with median overall survival in the whole cohort being 16.2 months (range 0.1–106.0) and perioperative mortality (GPS 0: 0.0% of perioperative deaths, GPS 1: 20.0%, GPS 2: 80.0%; P  = .036). Furthermore, GPS was identified as an independent prognosticator of overall survival ( P  = .033). A gradual decrease in survival between GPS subgroups was evident. Conclusion GPS represents an independent prognostic factor for long-term outcome in resected gastric cancer patients without perioperative treatment and is strongly associated with perioperative mortality.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>C-Reactive Protein - metabolism</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - surgery</subject><subject>Female</subject><subject>Gastrectomy</subject><subject>Humans</subject><subject>Lymph Node Excision</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Serum Albumin</subject><subject>Severity of Illness Index</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - surgery</subject><subject>Surgery</subject><subject>Survival Rate</subject><issn>0039-6060</issn><issn>1532-7361</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Ut2K1DAYDaK44-gLeCG59KZj0jZpAiLIoquwoLB6HdLk65gxbcYk7TrP4EubMqvCXgghP-Sck3znfAg9p2RHCeWvDrs0x_2uLvsdoWWIB2hDWVNXXcPpQ7QhpJEVJ5xcoCcpHQghsqXiMbqouZCy7egG_bryOu3DLf4cw34KKTuDb0yIgEd9wj1gjY__btxk4SceQsRhgai9x3qy-AjRhTLp7BbA5U-LW7QvYLzXKcfCM3oyEPGty9_CnO8RcgSdR5jyU_Ro0D7Bs7t1i76-f_fl8kN1_enq4-Xb68q0lOaK90wCE0IbwqSEjrHB2pbx2liwA_QgRTkMtextsaTpgVI9UGCtaAUZjGi26OVZt1T2Y4aU1eiSAe_1BGFOinaiI5JLxgq0PkNNDClFGNQxulHHk6JErSGog1pDUGsIilC1vrhFL-70534E-5fyx_UCeH0GQKlycRBVMg6KRdZFMFnZ4P6v_-Ye3Xg3OaP9dzhBOoQ5TsU_RVWqFVE3axusXUB56QAu2uY34puxeg</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Melling, Nathaniel, MD</creator><creator>Grüning, Amica, MD</creator><creator>Tachezy, Michael, MD</creator><creator>Nentwich, Michael, MD</creator><creator>Reeh, Matthias, MD</creator><creator>Uzunoglu, Faik G., MD</creator><creator>Vashist, Yogesh K., MD</creator><creator>Izbicki, Prof, Jakob R., MD</creator><creator>Bogoevski, Dean, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160601</creationdate><title>Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment</title><author>Melling, Nathaniel, MD ; Grüning, Amica, MD ; Tachezy, Michael, MD ; Nentwich, Michael, MD ; Reeh, Matthias, MD ; Uzunoglu, Faik G., MD ; Vashist, Yogesh K., MD ; Izbicki, Prof, Jakob R., MD ; Bogoevski, Dean, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-6b59e588ac0599e755fdd4562cdedfebe98562f29bd0183be11af1e548480fc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>C-Reactive Protein - metabolism</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - surgery</topic><topic>Female</topic><topic>Gastrectomy</topic><topic>Humans</topic><topic>Lymph Node Excision</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Serum Albumin</topic><topic>Severity of Illness Index</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - surgery</topic><topic>Surgery</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Melling, Nathaniel, MD</creatorcontrib><creatorcontrib>Grüning, Amica, MD</creatorcontrib><creatorcontrib>Tachezy, Michael, MD</creatorcontrib><creatorcontrib>Nentwich, Michael, MD</creatorcontrib><creatorcontrib>Reeh, Matthias, MD</creatorcontrib><creatorcontrib>Uzunoglu, Faik G., MD</creatorcontrib><creatorcontrib>Vashist, Yogesh K., MD</creatorcontrib><creatorcontrib>Izbicki, Prof, Jakob R., MD</creatorcontrib><creatorcontrib>Bogoevski, Dean, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Melling, Nathaniel, MD</au><au>Grüning, Amica, MD</au><au>Tachezy, Michael, MD</au><au>Nentwich, Michael, MD</au><au>Reeh, Matthias, MD</au><au>Uzunoglu, Faik G., MD</au><au>Vashist, Yogesh K., MD</au><au>Izbicki, Prof, Jakob R., MD</au><au>Bogoevski, Dean, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment</atitle><jtitle>Surgery</jtitle><addtitle>Surgery</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>159</volume><issue>6</issue><spage>1548</spage><epage>1556</epage><pages>1548-1556</pages><issn>0039-6060</issn><eissn>1532-7361</eissn><abstract>Background Systemic inflammation is a key factor in tumor growth. C-reactive protein and albumin are parameters of systemic inflammation from the Glasgow Prognostic Score (GPS). The purpose was to evaluate the prognostic role of GPS in a homogeneous population of gastric cancer patients undergoing surgical treatment only. Methods Patients underwent operations between 2009 and 2014. Those who had received perioperative treatment or had other malignancies or inflammatory diseases were excluded. Eighty-eight patients met all inclusion criteria (age &gt;18 years, documented preoperative serum levels of albumin and C-reactive protein, histologically proven gastric cancer, curative operation, including lymphadenectomy). C-reactive protein and albumin levels were retrieved from our prospective database. GPS was correlated with clinicopathologic characteristics and outcome. Results Increasing GPS was linked to aggressive tumor biology in terms of tumor size (GPS 0: 51.2% T1 and T2, 48.8% T3 and T4; GPS 1: 23.8% T1 and T2, 76.2% T3 and T4; GPS 2: 23.1% T1 and T2, 76.9% T3 and T4; P  = .026), synchronous distant metastases (GPS 0: 47.1% M0, 0.0% M1; GPS 1: 25.9% M0, 0.0% M1; GPS 2: 27.1% M0, 100.0% M1; P  = .030), venous vessel invasion (GPS 0: 91.2% V0, 8.8% V1; GPS 1: 66.7% V0, 33.3% V1; GPS 2: 55.0% V0, 45.0% V1; P  = .008), resection margin status (GPS 0: 97.4% R0, 2.6% R1; GPS 1: 90.0% R0, 10.0% R1; GPS 2: 77.3% R0, 22.7% R1; P  = .044), reduced overall survival (GPS 0: median 25.2 months [range 0.4–106.0]; GPS 1: 15.3 [0.2–59.5]; GPS 2: 5.8 [0.1–55.3]; P  = .016) with median overall survival in the whole cohort being 16.2 months (range 0.1–106.0) and perioperative mortality (GPS 0: 0.0% of perioperative deaths, GPS 1: 20.0%, GPS 2: 80.0%; P  = .036). Furthermore, GPS was identified as an independent prognosticator of overall survival ( P  = .033). A gradual decrease in survival between GPS subgroups was evident. Conclusion GPS represents an independent prognostic factor for long-term outcome in resected gastric cancer patients without perioperative treatment and is strongly associated with perioperative mortality.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26899471</pmid><doi>10.1016/j.surg.2016.01.018</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0039-6060
ispartof Surgery, 2016-06, Vol.159 (6), p.1548-1556
issn 0039-6060
1532-7361
language eng
recordid cdi_proquest_miscellaneous_1787096955
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adult
Aged
Aged, 80 and over
C-Reactive Protein - metabolism
Carcinoma - mortality
Carcinoma - pathology
Carcinoma - surgery
Female
Gastrectomy
Humans
Lymph Node Excision
Male
Middle Aged
Neoplasm Staging
Prognosis
Retrospective Studies
Serum Albumin
Severity of Illness Index
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Surgery
Survival Rate
title Glasgow Prognostic Score may be a prognostic index for overall and perioperative survival in gastric cancer without perioperative treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A41%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glasgow%20Prognostic%20Score%20may%20be%20a%20prognostic%20index%20for%20overall%20and%20perioperative%20survival%20in%20gastric%20cancer%20without%20perioperative%20treatment&rft.jtitle=Surgery&rft.au=Melling,%20Nathaniel,%20MD&rft.date=2016-06-01&rft.volume=159&rft.issue=6&rft.spage=1548&rft.epage=1556&rft.pages=1548-1556&rft.issn=0039-6060&rft.eissn=1532-7361&rft_id=info:doi/10.1016/j.surg.2016.01.018&rft_dat=%3Cproquest_cross%3E1787096955%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1787096955&rft_id=info:pmid/26899471&rft_els_id=1_s2_0_S0039606016000684&rfr_iscdi=true